Table 1.
Baseline characteristics recorded before active run-ina
| Variable | Randomized Treatment
|
|
|---|---|---|
| Perindopril-Indapamide (n = 5569) | Placebo (n = 5571) | |
| Age (yr; mean [SD]) | 66 (6) | 66 (7) |
| Female (n [%]) | 2366 (42.5) | 2369 (42.5) |
| Age when diabetes first diagnosed (yr; mean [SD]) | 58 (9) | 58 (9) |
| Duration of diabetes (yr; mean [SD]) | 8 (6) | 8 (6) |
| BP control (mmHg; mean [SD]) | ||
| SBP | 145 (22) | 145 (21) |
| DBP | 81 (11) | 81 (11) |
| history of currently treated hypertension (n [%]) | 3802 (68.3) | 3853 (69.2) |
| Renal parameters | ||
| UACR (μg/mg; median [IQR]) | 15 (7 to 40) | 15 (7 to 40) |
| microalbuminuria (n [%]) | 1441 (25.9) | 1421 (25.5) |
| macroalbuminuria (n [%])b | 197 (3.5) | 204 (3.7) |
| serum creatinine (μmol/L; mean [SD])c | 87 (23) | 87 (26) |
| eGFR (ml/min per 1.73 m2; mean [SD]) | 78 (25) | 78 (25) |
| eGFR <60 ml/min per 1.73 m2 (n [%]) | 1063 (19.1) | 1094 (19.6) |
| Previous vascular disease | ||
| history of major macrovascular disease (n [%]) | 1798 (32.3) | 1792 (32.2) |
| history of myocardial infarction (n [%]) | 678 (12.2) | 656 (11.8) |
| history of stroke (n [%]) | 502 (9.0) | 520 (9.3) |
| history of microvascular eye disease (n [%])d | 389 (7.0) | 404 (7.3) |
| Other major risk factors | ||
| current smoker (n [%]) | 804 (14.4) | 878 (15.8) |
| serum total cholesterol (mmol/L; mean [SD])e | 5.2 (1.2) | 5.2 (1.2) |
| serum HDL cholesterol (mmol/L; mean [SD])e | 1.3 (0.3) | 1.3 (0.4) |
| serum HbA1c concentration (%; mean [SD]) | 7.5 (1.6) | 7.5 (1.6) |
| body weight (kg; mean [SD]) | 78.3 (16.8) | 78.0 (16.8) |
| BMI (kg/m2; mean [SD]) | 28.3 (5.2) | 28.3 (5.1) |
| waist-to-hip ratio (mean [SD]) | 0.93 (0.08) | 0.93 (0.08) |
| Region of origin (n [%]) | ||
| Europe | 2539 (45.6) | 2544 (45.7) |
| Asia | 2070 (37.2) | 2066 (37.1) |
| Treatment (n [%]) | ||
| ACEIs | 2402 (43.1) | 2388 (42.9) |
| ARBs | 289 (5.2) | 320 (5.7) |
| calcium channel blockers | 1669 (30.0) | 1758 (31.6) |
| β blockers | 1344 (24.1) | 1385 (24.9) |
| diuretics | 1260 (22.6) | 1247 (22.4) |
| antiplatelets | 2597 (46.6) | 2601 (46.7) |
| lipid-modifying drugs | 1938 (34.8) | 1996 (35.8) |
a
Reprinted in part from Patel et al.,18 with permission from Elsevier. ARB, angiotensin receptor blocker; BMI, body mass index; HbA1c, glycosylated hemoglobin; IQR, interquartile range.
b
UACR >300 μg/mg.
c
To convert values to mg/dl, divide by 88.4.
d
Proliferative diabetic retinopathy, retinal photocoagulation therapy, macular edema, or blindness in one eye thought to be caused by diabetes.
e
To convert values to mg/dl, divide by 0.259.